- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 23.09. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum | 2 | GlobeNewswire (USA) | ||
| 23.09. | H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock | 1 | Investing.com | ||
| 21.08. | Cantor Fitzgerald bestätigt "Overweight"-Rating für Aardvark Therapeutics und sieht über 400 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 21.08. | Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock | 2 | Investing.com | ||
| 14.08. | Cantor Fitzgerald: Erfolgschancen der Phase-3-Studie von Aardvark Therapeutics massiv unterbewertet | 8 | Investing.com Deutsch | ||
| 14.08. | Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock | 2 | Investing.com | ||
| 13.08. | Aardvark Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 74 | GlobeNewswire (Europe) | Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing... ► Artikel lesen | |
| 12.08. | Aardvark Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following ... | 166 | GlobeNewswire (Europe) | In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain... ► Artikel lesen | |
| 18.07. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) | 147 | GlobeNewswire (Europe) | SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics... ► Artikel lesen | |
| 30.06. | H.C. Wainwright nimmt Aardvark Therapeutics-Aktie mit Kaufempfehlung auf | 3 | Investing.com Deutsch | ||
| 30.06. | H.C. Wainwright initiates coverage on Aardvark Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 19.05. | Aardvark Therapeutics strukturiert Führungsteam während Phase-3-Studie um | 2 | Investing.com Deutsch | ||
| 19.05. | Aardvark Therapeutics reshuffles leadership amid Phase 3 study | 2 | Investing.com | ||
| 19.05. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions | 192 | GlobeNewswire (Europe) | Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian... ► Artikel lesen | |
| 15.05. | Aardvark Therapeutics reports Q1 results | 2 | Seeking Alpha | ||
| 14.05. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
| QIAGEN | 39,470 | +0,71 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,612 | +4,36 % | Evotec Aktie - das große Zittern: Kurssturz Richtung 5 Euro? | Wieder ein Fehlausbruch bei der Evotec Aktie: Der Biotech-Titel hat diesmal bereits an der 50-Tage-Linie den Weg nach unten angetreten - zuvor passierten diese Fehlausbrüche an der spürbar höher liegenden... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| BIONTECH | 89,10 | -0,11 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,620 | +2,23 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
| APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |
AARDVARK THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 15,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.